Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Orphan drug designation for pancreatic cancer candidate
January 2015
by  |  Email the author
EDIT CONNECT

SHARING OPTIONS:

CAMBRIDGE, Mass.—The U.S. Food and Drug Administration (FDA) has granted MM-141 orphan drug designation for the treatment of pancreatic cancer, Merrimack Pharmaceuticals Inc. reported recently. The investigational compound is a tetravalent bispecific antibody designed to block tumor survival signals by targeting receptor complexes containing IGF-1R and ErbB3. This designation grants Merrimack seven-year marketing exclusivity for MM-141 should the drug receive FDA approval. A Phase 2 study investigating MM-141 combined with nab-paclitaxel and gemcitabine in frontline pancreatic cancer is expected to start next year.
 
Dr. Ulrik Nielsen, Merrimack's chief scientific officer and co-founder, called the designation “an important regulatory advancement in the development of our clinical program,” adding that “We look forward to advancing the clinical development of MM-141 as we believe that it has the potential to significantly inhibit tumor survival signaling and address pathways of therapeutic resistance in this indication.”
 
Code:

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.